TEL AVIV, Israel, Feb. 02, 2016 (GLOBE NEWSWIRE) -- Alcobra Ltd. (Nasdaq:ADHD), an emerging pharmaceutical company focused on the development of new medications to help patients with cognitive disorders, including Attention Deficit Hyperactivity Disorder (ADHD) and Fragile X Syndrome, today announced that it will report its financial results for the fourth quarter and fiscal year ended December 31, 2015 before the market open, and will host a corporate update conference call and webcast on Wednesday, February 17 at 8:30 am Eastern Time.
| Conference Call & Webcast | |
| Wednesday, February 17, 2016 @ 8:30am Eastern Time | |
| Domestic: | 855-469-0611 |
| International: | 484-756-4341 |
| Passcode: | 34475008 |
| Webcast: | http://www.alcobra-pharma.com/events.cfm |
| Replays available through March 2, 2016 | |
| Domestic: | 855-859-2056 |
| International: | 404-537-3406 |
| Passcode: | 34475008 |
About Alcobra
Alcobra Ltd. is an emerging pharmaceutical company primarily focused on the development and commercialization of a proprietary drug candidate, MDX, to treat cognitive disorders including ADHD and FXS. For more information please visit the Company's website, www.alcobra-pharma.com, the content of which is not incorporated herein by reference.